At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 72 enrolled
Drug / intervention
Onvansertib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of PCM-075 (Onvansertib) in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Onvansertib, Abiraterone, and 1 other intervention for Metastatic Castration-Resistant Prostate Cancer. Completed, enrolled 72 participants across 3 sites.
Detailed Summary
The purpose of the phase 2 study is to determine whether Onvansertib is safe and tolerable in adult participants with Metastatic Castration-Resistant Prostate Cancer who have disease progression while receiving abiraterone acetate (abiraterone) and prednisone therapy, and to observe the effects of Onvansertib in combination with abiraterone and prednisone on disease control.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 2018
Enrollment StartAug 2018
Primary CompletionOct 2023
TodayJul 2026
First PostedJan 29, 2018
Enrollment StartAug 14, 2018
Primary CompletionOct 16, 2023
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 8.4 years ago
Interventions
Onvansertibdrug
Onvansertib orally
Abirateronedrug
Abiraterone orally
Prednisonedrug
Prednisone orally